It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (EDIT -0.98%) have collapsed by about 88% over the past three years despite recent positive news regarding its experimental therapies and intellectual property.Editas is driving its first CRISPR-based therapy toward commercialization. Following approval of a similar treatment from CRISPR Therapeutics and partner Vertex Pha ...

Dima, Tristan, & Stephanie 1 January 2024 Forward Looking Statements This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forwar ...

Editas Medicine, Inc. (NASDAQ:EDIT) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 7:30 PM ET Company Participants Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Conference Call Participants Brian Cheng - J.P. Morgan Brian Cheng Good afternoon. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng, I'm one of the Senior Biotech Analysts here at the firm. I'm joined by my associate, Sean Kim, who is also in the audience. On stage, ...

Editas Medicine, Inc. (NASDAQ:EDIT) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 7:30 PM ET Company Participants Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Conference Call Participants Brian Cheng - J.P. Morgan Brian Cheng Good afternoon. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng, I'm one of the Senior Biotech Analysts here at the firm. I'm joined by my associate, Sean Kim, who is also in the audience. On stage, ...

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP Strong financial position with operational runway into 2026 Company to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PST CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, ...

Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (EDIT -4.72%) and Intellia Therapeutics (NTLA -3.02%) are both exciting gene-editing businesses that aspire to treat or cure human illnesses using some of the most advanced biotechnologies that exist at the moment.But there's a clear winner of this matchup when it comes to which is the more attractive opportunity to inves ...

It's fair to say that Editas Medicine (EDIT 4.74%) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff. Despite its supposedly powerful gene-editing technology, the company is struggling to advance its clinical programs to the point where they might be commercialized and generate revenue.Thankfully for Editas shareholders, Vertex Pharmaceuticals (VRTX 1.15%) just gave the business a much-needed break -- one that might ev ...

Editas Medicine, Inc. (NASDAQ:EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Caren Deardorf - Chief Commercial & Strategy Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Joon Lee - Truist Securities Samantha Semenkow - Citigroup Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Markets Phil Nadeau - TD Cowen Dae Gon Ha - Stife ...

Editas Medicine, Inc. (NASDAQ:EDIT) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - Head, Corporate Communications & IR Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Thanks for joining us today for a fireside chat with Editas. My name is Liisa Bayko. I'm a biotech analyst at Evercore ISI, and I'm joined by the team here at Editas. So I'll just turn over. You can do some brief introductions and we'll the ...

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2023 Healthcare Conference November 14, 2023 1:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha Okay, let's go ahead and get started with the next session. Thanks everyone for joining us. For the next half hour or so, we're going to be talking Editas Medicine. My name is Dae Gon Ha, biotech analyst at Stifel. Joining me here on stage, we have Erick ...